دراسة ارتباط بين انخفاض الوزن و الخضاب الغلوكوزي عند مرضى معالجين بالغليفلوزين

Abstract EN

Background and objective : Type 2 diabetes (T2DM) is a metabolic disease that is often associated with obesity.

Sodium/glucose cotransporter-2 inhibitors (SGLT2i) are a relatively new class that leads to glycated haemoglobin (HbA1C) reduction as a result of increasing urinary glucose excretion (the amount of glucose excreted by gliflozin increases as the plasma glucose levels increases) and subsequently decreasing calories which cause body weight reduction.

Therefore, it was proposed that the effect of gliflozin in HbA1c-reduction would correlate with body weight reduction.

Materials and Methods : This study was a randomized, triple-blind, crossover, 24-week monocenter Trial.

T2DM Patients were randomized to receive metformin 1000 mg b.i.d with the highest dose of gliflozin (Empagliflozin 25 m g/day (n=19) and then Dapagliflozin 10 mg/day (n=18) or vice versa).

Each treatment period was 12 weeks with a 7-10 day washout period in between.

The parameters were evaluated at baseline and after 12 and 24 weeks.

At the end of the study, the correlation between HbA1C and body weight reduction of Empagliflozin and Dapagliflozin was assessed.

Results : No significant association was found between the two outcomes in the Empagliflozin group (R= -0.208; p=0.216).

whereas, a significant moderate positive association was found between the two outcomes in the Dapagliflozin group (R= +0.575; p=0.000).

Conclusion : Our study indicated that there is a difference in the studied correlation between the two drugs Dapagliflozin and Empagliflozin used in the same patients, which highlights the possibility of pharmacodynamic differences between these two drugs despite them belonging to the same therapeutic class and having the same pharmacological mechanism, which leads to differences in the therapeutic outcomes.

This confirms the necessity of conducting Research investigating these differences to achieve better efficacy.